Deleted: . ... [4] ... [28] ... [11] ... [16] ... [27] ... [22] ... [12] ... [5] ... [23] ... [6] ... [24] ... [31] ... [14] ... [32] ... [15] ... [26] ... [7] ... [33] ... [25] ... [17] ... [9] ... [18] ... [10] ... [19] ... [1] ... [20] ... [2] ... [8] ... [3] ... [29] ... [13] ... [30] ... [21] different studies. [24, 25] Although the therapeutic inefficacy of Imatinib monotherapy for mesothelioma has been recently reported [25, 26] , combination therapies with Imatinib in mice yielded successful results. [27, 28] Gemcitabine, Cisplatin, Etoposide, Doxorubicin and, more recently, Pemetrexed have been demonstrated to be active for MMe treatment. Combined therapy Cisplatin/Pemetrexed and Cisplatin/Gemcitabine have been demonstrated more effective than each single agents used alone. [29] The aim of the present study is to investigate a translational approach which assessing the possible efficacy of Imatinib, as a single agent or in combined therapy for MMe.
Methods

Cell cultures. Mesothelioma cells were derived from pleural effusions and stabilized in culture as continuous cell lines. MMP cells and primary Human Mesothelial Cells (HMC)
were characterized and cultured as previously described.
[5] REN cells were kindly provided by Dr. Albelda and ISTMES2 were from the IST cell depository of Genoa (Italy).
Drugs. Imatinib was kindly provided by Novartis (Basel, Switzerland); Gemcitabine and
Pemetrexed by Lilly (Indianapolis, IN). Commercially available Cisplatin, Doxorubicin and Etoposide were from Alexis (Lausen, Switzerland).
Signal transduction. Cells were grown in 0.2 % Foetal Bovine Serum (FBS) for 24 h, then pre-incubated for 90 min in presence or absence of 10 µM Imatinib. To the same medium 20 ng/ml purified PDGF (R&D, Milan, Italy) was added. Immunoprecipitation and immunoblotting were performed as previously described.
[5] Antibodies used were: PDGFRβ, phospho-PDGFRβ, c-Kit, c-Fms (Santa Cruz Biotechnology, USA), phospho-Akt-Ser473 (Cell Signaling, USA), phosphotyrosine (UBI, USA) and phospho-Erk1/2 (Sigma, USA).
Reactions were detected by Enhanced Chemiluminescence System (ECL, Amersham, UK). In all statistical evaluations the significance threshold was specified in the text. 
Results
PDGFRβ
Imatinib-mediated PDGFRβ inhibition selectively affects Akt. MMe cells positive for
PDGFRβ, were also tested by immunoprecipitation with PDGFRβ antibodies followed by (Fig 2 A) .
We did not observe any evidence of PDGFRβ phosphorylation/activation by any of the two chemotherapeutic agents ( Supplementary Fig. 2 The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence on a worldwide basis to the BMJ Publishing Group
Ltd and its Licensees to permit this article to be published in Thorax editions and any other BMJPG Ltd products to exploit all subsidiary rights, as set out in our licence (http://thorax.bmjjournals.com/ifora/licence.pdf). 
Figure legends
